Refractory Glaucoma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Refractory glaucoma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Refractory Glaucoma Today - Breaking & Trending Today

Myra Vision, A Shifamed Portfolio Company, Closes $17M In Series A Financings

Myra Vision, A Shifamed Portfolio Company, Closes $17M In Series A Financings
Company to accelerate development of the first-of-its-kind treatment for patients with moderate to severe glaucoma
News provided by
Share this article
Share this article
CAMPBELL, Calif., June 1, 2021 /PRNewswire/ Myra Vision, a Shifamed portfolio company, announced today the closing of its $17M Series A financings, which will be used to advance product development, scale infrastructure, and expand their team in order to support the development of the first of its kind glaucoma treatment device. The financings were led by The Capital Partnership (TCP), with participation from Cormorant Asset Management and Shifamed angel investors. In conjunction with the financing, the company has changed its name to Myra Vision, Inc. from Myra Medical, Inc. ....

Amr Salahieh , Katie Arnold , Robert Chang , Casey Gordon , Myra Vision Inc , Capital Partnership , Myra Medical Inc , Myra Vision , Cormorant Asset Management , Myra Medical , Private Investments , New Ab Interno Gelatin Stent , Refractory Glaucoma , கேடீ அர்னால்ட் , ராபர்ட் சாங் , வழக்கு கோர்டந் , மூலதனம் கூட்டு , கர்மரண்ட் சொத்து மேலாண்மை , ப்ரைவேட் முதலீடுகள் ,

Aerie Pharmaceuticals Announces Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Published: Apr 28, 2021

DURHAM, N.C. (BUSINESS WIRE) Aerie Pharmaceuticals, Inc.. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced it will participate and have poster presentations at the virtual Association for Research and Vision in Ophthalmology (ARVO) Annual Meeting, to be held May 1-7, 2021. The posters will highlight topics ranging from additional research findings on netarsudil to potential new product candidates such as the new class of corticosteroid anti-inflammatories.
The following posters are independent research and not sponsored by Aerie Pharmaceuticals: ....

United States , Nate Goergen , Kevin Carbajal , Vladislav Bekerman , Reza Kianian , Maria Zaretskaia , Casey Kopczynski , Leslie Ramos , Natacha Villega , Timothy Janetos , Schepens Eye Research Institute Of Massachusetts , University Of Nebraska Medical Center , Aerie Pharmaceuticals Inc , Drug Administration , Northwestern University Feinberg School Of Medicine , Exchange Commission , European Medicines Agency , Tertiary Care Center , Association For Research , Stanford University , Aerie Pharmaceuticals , Annual Meeting , Northwestern University Feinberg School , Adjunctive Use , Refractory Glaucoma , Retrospective Analysis ,

Aerie Pharmaceuticals Announces Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Press release content from Business Wire. The AP news staff was not involved in its creation.
Aerie Pharmaceuticals Announces Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
April 28, 2021 GMT
DURHAM, N.C. (BUSINESS WIRE) Apr 28, 2021
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced it will participate and have poster presentations at the virtual Association for Research and Vision in Ophthalmology (ARVO) Annual Meeting, to be held May 1-7, 2021. The posters will highlight topics ranging from additional research findings on netarsudil to potential new product candidates such as the new class of corticosteroid anti-inflammatories. ....

United States , Nate Goergen , Kevin Carbajal , Vladislav Bekerman , Reza Kianian , Maria Zaretskaia , Casey Kopczynski , Leslie Ramos , Natacha Villega , Timothy Janetos , Schepens Eye Research Institute Of Massachusetts , University Of Nebraska Medical Center , Aerie Pharmaceuticals Inc , Drug Administration , Northwestern University Feinberg School Of Medicine , Exchange Commission , European Medicines Agency , Tertiary Care Center , Association For Research , Stanford University , Aerie Pharmaceuticals , Annual Meeting , Northwestern University Feinberg School , Adjunctive Use , Refractory Glaucoma , Retrospective Analysis ,